Dabrafenib Mesylate

3 trials 1 recruiting Orphan designation

Filter these 3 trials by condition, phase, country and more.

Open in Search →

3 Registered trials

1 Recruiting

2 Completed trials

1 Sponsors

13 Countries

Phase IV

Phase I (Other)

Phase IV: 2 Phase I (Other): 1

Indications tested

Neoplasm malignant 1 Non-small cell lung cancer 1

Sponsors using this IMP

Novartis Pharma AG 3

All trials

3 total

Study to allow access to dabrafenib and/or trametinib for subjects that are benefiting from dabrafenib and/or trametinib treatment in a Nova… Recruiting

2023-509318-13-00 Phase IV 7 countries Novartis Pharma AG
Rollover study for continued safety and tolerability in subjects treated with spartalizumab alone or in combination with other study treatme… Ended

2023-508841-42-00 Phase I (Other) 8 countries Novartis Pharma AG
This study will facilitate data collection of the long-term outcomes of pediatric subjects who have been treated in clinical trials with dab… Ended

2023-509276-42-00 Phase IV 10 countries Novartis Pharma AG

Showing 1–3 of 3 trials

← All drugs A–Z